UCB: buys US biotech company for E2bn
(CercleFinance.com) - The Belgian pharmaceutical group UCB will buy the US biotech compan Ra Pharmaceuticals for a net sum of about two billion euros, both companies have said.
Recommended by the target, a 48-dollar cash offer per Ra Pharmaceuticals share, which is listed on Nasdaq, will be launched, which represents an instant premium of over 100% relative to the last listed price.
Ra is particularly present in the treatment of rare diseases such as myasthenia, a neuro-muscular pathology.
UCB, which has also confirmed its financial forecasts for 2019, believes that this deal will accelerate its sales and earnings growth from 2024.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Recommended by the target, a 48-dollar cash offer per Ra Pharmaceuticals share, which is listed on Nasdaq, will be launched, which represents an instant premium of over 100% relative to the last listed price.
Ra is particularly present in the treatment of rare diseases such as myasthenia, a neuro-muscular pathology.
UCB, which has also confirmed its financial forecasts for 2019, believes that this deal will accelerate its sales and earnings growth from 2024.
Copyright (c) 2019 CercleFinance.com. All rights reserved.